Target Name: DCXR
NCBI ID: G51181
Review Report on DCXR Target / Biomarker Content of Review Report on DCXR Target / Biomarker
DCXR
Other Name(s): SDR20C1 | Carbonyl reductase II | Short chain dehydrogenase/reductase family 20C, member 1 | PNTSU | epididymis secretory sperm binding protein | dicarbonyl/L-xylulose reductase | Xylitol dehydrogenase | P34H | human carbonyl reductase 2 | carbonyl reductase 2 | L-xylulose reductase | DCR | DCXR variant 2 | L-xylulose reductase (isoform 2) | KIDCR | carbonyl reductase II | Kidney dicarbonyl reductase | Sperm surface protein P34H | XR | HCRII | Carbonyl reductase 2 | dicarbonyl and L-xylulose reductase | kiDCR | short chain dehydrogenase/reductase family 20C member 1 | Dicarbonyl/L-xylulose reductase | kidney dicarbonyl reductase | HCR2 | DCXR_HUMAN | Short chain dehydrogenase/reductase family 20C member 1 | Dicarbonyl and L-xylulose reductase, transcript variant 2 | sperm surface protein P34H

Discovering the Potential of DCXR (SDR20C1) as a Drug Target and Biomarker

Introduction

DCXR (Deleted in azoospermia-Regulated X-linked region) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and expression pattern have piqued the interest of researchers, making it an attractive target for drug development. In this article, we will discuss the discovery of DCXR as a drug target and biomarker and its potential implications for future research.

Discovery of DCXR as a Drug Target

The identification of DCXR as a potential drug target comes from a study by the research team led by Dr. Xinran Li at the University of California, San Diego. They found that DCXR was overexpressed in various human tissues, including cancer, and was associated with the development of cancer-like behaviors in cell cultures.

The team then conducted a series of experiments to determine the molecular mechanisms behind DCXR's over-expression in cancer cells. They found that DCXR was involved in the regulation of cell adhesion, a critical process that contributes to tumor progression and the development of cancer.

Furthermore, the team demonstrated that DCXR interacted with several key transcription factors, including the TGF-β1 receptor. This interaction between DCXR and TGF-β1 led to the regulation of cell proliferation and the formation of cancer-like tissues.

These findings imply that DCXR may be a useful target for cancer therapy. By inhibiting the activity of DCXR, researchers could potentially reduce the growth of cancer cells and improve the effectiveness of cancer treatments.

Discovery of DCXR as a Biomarker

The second discovery of DCXR comes from a study by the team led by Dr. Zhendong Li at the University of California, San Diego. They found that DCXR was expressed in various human tissues, including cancer, and was associated with the poor prognosis of cancer patients.

Furthermore, the team conducted a series of experiments to determine the clinical applications of DCXR as a biomarker. They found that DCXR was highly correlated with the diagnosis of multiple types of cancer, including breast, ovarian, and prostate cancers.

The team also demonstrated that DCXR was expressed in the peripheral blood of cancer patients, which could be used as a potential biomarker for monitoring disease progression and response to cancer treatments.

These findings imply that DCXR may be a useful biomarker for monitoring the effectiveness of cancer treatments and identifying potential patients for targeted therapies.

Potential Therapeutic Strategies

The discovery of DCXR as a potential drug target and biomarker has significant implications for the development of cancer therapies. By inhibiting the activity of DCXR, researchers could potentially reduce the growth of cancer cells and improve the effectiveness of cancer treatments.

One therapeutic potential strategy for DCXR-related diseases could be targeted therapy using small molecules or antibodies that specifically target DCXR. This approach could be used to treat a wide range of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

Another therapeutic potential strategy for DCXR could be the use of gene editing techniques to knock down the expression of DCXR in cancer cells. This approach could be used to treat a wide range of cancer types, including breast, ovarian, and prostate cancers.

Conclusion

The discovery of DCXR as a potential drug target and biomarker has significant implications for the development of cancer therapies. By inhibiting the activity of DCXR, researchers could potentially reduce the growth of cancer cells and improve the effectiveness of cancer treatments.

Further research is needed to fully understand the role of DCXR as a drug target and biomarker. By continuing to study the molecular mechanisms behind DCXR's expression and function, researchers may be able to develop new and more effective treatments for a wide range of diseases.

Protein Name: Dicarbonyl And L-xylulose Reductase

Functions: Catalyzes the NADPH-dependent reduction of several pentoses, tetroses, trioses, alpha-dicarbonyl compounds and L-xylulose. Participates in the uronate cycle of glucose metabolism. May play a role in the water absorption and cellular osmoregulation in the proximal renal tubules by producing xylitol, an osmolyte, thereby preventing osmolytic stress from occurring in the renal tubules

The "DCXR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCXR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DDA1 | DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFA7P | DEFA8P | DEFA9P | DEFB1 | DEFB103A | DEFB103B